- Investing Ideas
- /
- Swiss Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Swiss Pharmaceuticals & Biotech Undervalued Stocks Based On Cash Flows
Results
2
0 new
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
2 companies
Galderma Group
Market Cap: CHF 27.5b
Operates as a dermatology company worldwide.
GALD
CHF 115.90
7D
7.6%
1Y
58.0%
SKAN Group
Market Cap: CHF 1.7b
Provides isolators, cleanroom devices, and decontamination processes for pharmaceutical and chemical industries in Europe, the Americas, Asia, and internationally.
SKAN
CHF 75.10
7D
4.5%
1Y
-8.9%